On August 30, 2024, Wang Ningli, an expert in ophthalmology and otolaryngology, academician of the International Academy of Ophthalmology, and president of the Henan Academy of Medical Sciences, led a team of experts to Henan Zhimei Pharmaceutical Co., Ltd. for work research and was warmly welcomed by the company's leaders and employees.

The expert team, accompanied by leaders from Wang Group and EMICRO Biomedicine Company, visited the company's comprehensive research building laboratory.

  After the visit, both the guest and host had a friendly and cordial discussion. General Manager Li Wei delivered a welcome speech. Dean Wang and the experts carefully watched the research and development process and project advantages of EMICRO Biomedicine's innovative drugs through electronic large screen PPT explanations, and asked some professional questions on site to listen to answers.

  Dr. Yang Yinke, Chief Medical Officer of the company, delivered a report on the new progress of EMICRO Biomedicine work. The report provided a detailed introduction from multiple aspects, including the current status of the company's innovative drugs, policy resources, clinical progress, long-term planning, and difficulties faced. Dean Wang and the expert team listened attentively and expressed their opinions. The leaders, experts, and members of both the host and guest attending the symposium had in-depth exchanges and discussions on the topic of "innovative drugs".

  Dean Wang Ningli and Chairman Wang Yuqiao expressed their opinions after a conversation. He said that the development of innovative drugs has a long cycle, high investment, and slow returns, making it difficult to do. Entrepreneurs must have responsibility, resilience, passion, love, and perseverance in order to achieve success. Dean Wang provides professional guidance and advice on talent introduction, financing, establishment of research institutes, and future directions. He highly praised the innovative achievements of EMICRO Biomedicine in the field of innovative drugs and put forward earnest expectations for the future development of the enterprise.